Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Brentuximab Vedotin Shows Curative Potential in Hodgkin Lymphoma

July 19th 2016

Brentuximab vedotin showed a 5-year overall survival rate of 41% for patients with relapsed or refractory classical Hodgkin lymphoma, suggesting a cure for some patients.

Obinutuzumab Falls Short in Phase III DLBCL Trial

July 18th 2016

Adding the anti-CD20 agent obinutuzumab (Gazyva) to CHOP chemotherapy in the frontline setting did not improve progression-free survival compared with the standard regimen of rituximab (Rituxan) plus CHOP in patients with diffuse large B-cell lymphoma.

FDA Lifts Clinical Hold on Phase II Trial of JCAR015 in ALL

July 13th 2016

After less than a week, the FDA has lifted a clinical hold placed on the phase II ROCKET study that is exploring the CAR T-cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

Clinical Hold Placed on Phase II Trial for JCAR015 in Adult ALL

July 9th 2016

The FDA has placed a clinical hold on a phase II study exploring the CD19-targeted CAR-T cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

EC Grants Brentuximab Vedotin New Indication for Hodgkin Lymphoma

July 6th 2016

The European Commission has approved brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.

Ibrutinib Granted Breakthrough Designation for Chronic GVHD

June 30th 2016

The FDA has granted a breakthrough therapy designation to ibrutinib has a potential treatment for patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.

Practical Experience with Iron Chelating Agents

June 28th 2016

Managing Side Effects in Iron Chelation Therapy

June 28th 2016

Deferasirox Formulations in Iron Overload

June 28th 2016

MDS: Iron Chelating Options

June 28th 2016

Deciding When to Treat Excess Iron

June 28th 2016

Improving Quality of Life and Survival in Patients with MDS

June 28th 2016

Monitoring Patients with Iron Overload

June 28th 2016

Excess Iron in MDS

June 28th 2016

Stem Cell Transplantation in Patients with MDS

June 28th 2016

The Effects of Blood Transfusions on Iron Accumulation

June 28th 2016

Classification and Characteristics of MDS

June 28th 2016

Disease Characteristics in MDS

June 28th 2016

Overview and Historical Perspective of MDS

June 28th 2016

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016